Chugai Pharmaceutical Co., Ltd. (CHGCY) は上場企業です ヘルスケア セクターの 製薬 業界で事業展開. 本社所在地は Tokyo, 日本. 現CEOは Osamu Okuda.
CHGCY を有する IPO日 2012-08-03, 5,026 名の正社員, に上場 Other OTC, 時価総額 $89.53B.
Chugai Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing, and global distribution of innovative medicines. The company maintains a diversified portfolio spanning oncology, osteoporosis, renal diseases, and neurology, with key marketed products including Avastin, Tecentriq, Herceptin, Actemra, and Hemlibra, alongside a robust pipeline of development candidates across multiple therapeutic areas. As a subsidiary of Roche Holding Ltd., Chugai leverages strategic alliances and collaborative research partnerships to advance its drug development initiatives. Founded in 1925 and headquartered in Tokyo, the company combines decades of pharmaceutical expertise with Roche's global resources and capabilities.
